You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCytarabine
Accession NumberDB00987  (APRD00499)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Structure
Thumb
Synonyms
1-beta-D-Arabinofuranosylcytosine
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
Ara-C
Arabinofuranosyl Cytidine
Citarabina
Cytarabine
Cytarabinum
Cytosine arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aj-cytarabineSolution100 mgIntrathecal; Intravenous; SubcutaneousAgila Jamp Canada IncNot applicableNot applicableCanada
Cytarabine - Pws 1gn/vialPowder, for solution1 gIntrathecal; Intravenous; SubcutaneousNovopharm Limited1995-12-312015-10-26Canada
Cytarabine - Pws 2gm/vialPowder, for solution2 gIntrathecal; Intravenous; SubcutaneousNovopharm Limited1995-12-312015-10-26Canada
Cytarabine - Pws 500mg/vialPowder, for solution500 mgIntrathecal; Intravenous; SubcutaneousNovopharm Limited1995-12-312015-10-26Canada
Cytarabine Inj 100mg/mlLiquid100 mgIntravenous; SubcutaneousDavid Bull Laboratories (Pty) Ltd.1992-12-311998-08-13Canada
Cytarabine InjectionSolution100 mgIntrathecal; Intravenous; SubcutaneousHospira, Inc.1996-09-23Not applicableCanada
Cytarabine Injection BPSolution100 mgIntrathecal; Intravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Cytarabine Injection, Mylan Std.Solution100 mgIntrathecal; Intravenous; SubcutaneousMylan PharmaceuticalsNot applicableNot applicableCanada
Cytarabine-pws 100mg/vialPowder, for solution100 mgIntrathecal; Intravenous; SubcutaneousNovopharm Limited1995-12-31Not applicableCanada
CytosarPowder, for solution100 mgIntrathecal; Intravenous; SubcutaneousPfizer1977-12-31Not applicableCanada
CytosarSolution20 mgIntrathecal; Intravenous; SubcutaneousPfizerNot applicableNot applicableCanada
CytosarPowder, for solution500 mgIntrathecal; Intravenous; SubcutaneousPfizer1977-12-31Not applicableCanada
CytosarPowder, for solution1 gIntrathecal; Intravenous; SubcutaneousPfizer1986-12-31Not applicableCanada
CytosarSolution100 mgIntrathecal; Intravenous; SubcutaneousPfizerNot applicableNot applicableCanada
CytosarPowder, for solution2 gIntrathecal; Intravenous; SubcutaneousPfizer1986-12-31Not applicableCanada
DepocytInjection, lipid complex50 mg/5mLIntrathecalSigma Tau Pharmaceuticals, Inc.2010-10-22Not applicableUs
DepocytSuspension10 mgIntrathecalSkyepharma Inc.2000-12-29Not applicableCanada
DepocyteInjection, suspension50 mgIntrathecalPacira Limited2001-07-11Not applicableEu
PMS-cytarabineSolution20 mgIntrathecal; Intravenous; SubcutaneousPharmascience Inc2014-01-16Not applicableCanada
PMS-cytarabineSolution100 mgIntrathecal; Intravenous; SubcutaneousPharmascience Inc2014-01-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CytarabineInjection20 mg/mLIntravenous; SubcutaneousPfizer Laboratories Div Pfizer Inc.2011-12-14Not applicableUs
CytarabineInjection2 g/20mLIntrathecal; Intravenous; SubcutaneousMylan Institutional2012-01-31Not applicableUs
CytarabineInjection, solution20 mg/mLIntrathecal; Intravenous; SubcutaneousHospira Worldwide, Inc.1990-06-04Not applicableUs
CytarabineInjection20 mg/mLIntravenous; SubcutaneousPfizer Laboratories Div Pfizer Inc.2011-12-14Not applicableUs
CytarabineInjection, solution100 mg/mLIntrathecal; Intravenous; SubcutaneousFresenius Kabi2004-11-29Not applicableUs
CytarabineInjection2 g/20mLIntrathecal; Intravenous; SubcutaneousPfizer Laboratories Div Pfizer Inc.2012-01-31Not applicableUs
CytarabineInjection, solution100 mg/mLIntrathecal; Intravenous; SubcutaneousHospira, Inc.1999-11-22Not applicableUs
CytarabineInjection2 g/20mLIntrathecal; Intravenous; SubcutaneousMylan Institutional2012-01-31Not applicableUs
CytarabineInjection, solution20 mg/mLIntravenousHospira, Inc.1990-08-31Not applicableUs
CytarabineInjection20 mg/mLIntravenous; SubcutaneousMylan Institutional2011-12-14Not applicableUs
CytarabineInjection, solution20 mg/mLIntravenous; SubcutaneousHospira, Inc.1994-02-28Not applicableUs
CytarabineInjection100 mg/5mLIntrathecal; Intravenous; SubcutaneousPfizer Laboratories Div Pfizer Inc.2011-12-14Not applicableUs
CytarabineInjection100 mg/5mLIntrathecal; Intravenous; SubcutaneousMylan Institutional2011-12-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ara-CGobbi
Cytosar-UPfizer
Brand mixturesNot Available
Categories
UNII04079A1RDZ
CAS number147-94-4
WeightAverage: 243.2166
Monoisotopic: 243.085520541
Chemical FormulaC9H13N3O5
InChI KeyUHDGCWIWMRVCDJ-CCXZUQQUSA-N
InChI
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
IUPAC Name
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
SMILES
NC1=NC(=O)N(C=C1)[C@@H]1O[[email protected]](CO)[C@@H](O)[C@@H]1O
Pharmacology
IndicationFor the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Structured Indications
PharmacodynamicsCytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.
Mechanism of actionCytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.
TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideyes
cross-linking/alkylation
Humannot applicabledetails
DNA polymerase betaProteinyes
inhibitor
HumanP06746 details
Related Articles
AbsorptionLess than 20% of the orally administered dose is absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein binding13%
Metabolism

Hepatic.

Route of eliminationThe primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U.
Half life10 minutes
ClearanceNot Available
ToxicityCytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cytarabine.Approved
AmiodaroneThe metabolism of Cytarabine can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Cytarabine can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Cytarabine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Cytarabine can be decreased when combined with Atomoxetine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Cytarabine.Approved, Investigational
BexaroteneThe serum concentration of Cytarabine can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Cytarabine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Cytarabine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cytarabine can be decreased when it is combined with Bosentan.Approved, Investigational
BupropionThe serum concentration of Cytarabine can be increased when it is combined with Bupropion.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cytarabine.Approved
CarbamazepineThe metabolism of Cytarabine can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibThe serum concentration of Cytarabine can be increased when it is combined with Ceritinib.Approved
ClarithromycinThe metabolism of Cytarabine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cytarabine can be decreased when combined with Clemastine.Approved
ClotrimazoleThe metabolism of Cytarabine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Clozapine.Approved
CobicistatThe metabolism of Cytarabine can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Cytarabine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Cytarabine can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cytarabine.Approved, Investigational
CyclosporineThe metabolism of Cytarabine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Cytarabine can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Cytarabine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Cytarabine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Cytarabine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cytarabine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cytarabine.Approved
DexamethasoneThe serum concentration of Cytarabine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cytarabine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Cytarabine.Approved
DihydroergotamineThe metabolism of Cytarabine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Cytarabine can be decreased when combined with Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.Approved, Investigational
DoxycyclineThe metabolism of Cytarabine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Cytarabine can be decreased when combined with Dronedarone.Approved
EfavirenzThe serum concentration of Cytarabine can be decreased when it is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Cytarabine can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Cytarabine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Cytarabine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EtravirineThe serum concentration of Cytarabine can be decreased when it is combined with Etravirine.Approved
FingolimodCytarabine may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe metabolism of Cytarabine can be decreased when combined with Fluconazole.Approved
FlucytosineThe therapeutic efficacy of Flucytosine can be decreased when used in combination with Cytarabine.Approved
FluvoxamineThe metabolism of Cytarabine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Cytarabine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cytarabine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Cytarabine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Cytarabine can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Cytarabine is combined with G17DT.Investigational
IdelalisibThe serum concentration of Cytarabine can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Cytarabine can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Cytarabine can be decreased when combined with Indinavir.Approved
INGN 201The risk or severity of adverse effects can be increased when Cytarabine is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cytarabine is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Cytarabine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Cytarabine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cytarabine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cytarabine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Cytarabine can be decreased when combined with Ketoconazole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Cytarabine is combined with Leflunomide.Approved, Investigational
LopinavirThe metabolism of Cytarabine can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Cytarabine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cytarabine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cytarabine can be increased when combined with Lumacaftor.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cytarabine.Withdrawn
MifepristoneThe serum concentration of Cytarabine can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Cytarabine can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Cytarabine can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Cytarabine can be decreased when it is combined with Nafcillin.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Cytarabine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cytarabine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cytarabine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cytarabine can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Cytarabine can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Cytarabine can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Cytarabine.Experimental
OsimertinibThe serum concentration of Cytarabine can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Cytarabine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cytarabine.Approved, Vet Approved
PalbociclibThe serum concentration of Cytarabine can be increased when it is combined with Palbociclib.Approved
PentobarbitalThe metabolism of Cytarabine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Cytarabine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Cytarabine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.Approved, Investigational
PosaconazoleThe metabolism of Cytarabine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Cytarabine can be increased when combined with Primidone.Approved, Vet Approved
RanolazineThe metabolism of Cytarabine can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Cytarabine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cytarabine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cytarabine can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Cytarabine is combined with CDX-110.Investigational
RitonavirThe metabolism of Cytarabine can be decreased when combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Cytarabine.Approved
SaquinavirThe metabolism of Cytarabine can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe metabolism of Cytarabine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cytarabine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cytarabine can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cytarabine.Approved
SRP 299The risk or severity of adverse effects can be increased when Cytarabine is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Cytarabine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Cytarabine can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Cytarabine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cytarabine.Approved, Investigational
TelaprevirThe metabolism of Cytarabine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Cytarabine can be decreased when combined with Telithromycin.Approved
TiclopidineThe metabolism of Cytarabine can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Cytarabine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCytarabine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cytarabine.Approved, Investigational
VenlafaxineThe metabolism of Cytarabine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cytarabine can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Cytarabine can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Cytarabine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Michael Kluge, Herbert Schott, “Cytarabine derivatives, the preparation and use thereof.” U.S. Patent US5641758, issued August, 1992.

US5641758
General ReferencesNot Available
External Links
ATC CodesL01BC01
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelDownload (49.8 KB)
MSDSDownload (36.8 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentMyelofibrosis1
0RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
0WithdrawnTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS / Neurotoxicity1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / AML / Leukemias1
1Active Not RecruitingTreatmentAcute Granulocytic Leukemia / Acute Myelocytic Leukemia / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML) / Acute Non-Lymphocytic Leukemia1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Myelodysplastic Syndrome / Ph1 Positive CML / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Advanced Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentLymphoma NOS / Lymphoma, B-Cell1
1Active Not RecruitingTreatmentLymphoma NOS / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1Active Not RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
1CompletedTreatmentAML / CML / Leukemias / Myeloid Leukemias1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Mixed Phenotype Acute Leukemia (MPAL) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML)2
1CompletedTreatmentAcute Myeloid Leukaemias (AML)3
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Acute Myeloid Leukemia With Multilineage Dysplasia Following / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Myelodysplastic Syndrome / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Biphenotypic Leukemia / Infantile Leukemia (Both AML and ALL) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Neoplasms, Malignant / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1CompletedTreatmentCancers / Leukemias1
1CompletedTreatmentChronic Myeloid Leukemia (CML)1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
1CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentHodgkins Disease (HD) / Lymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemia, Myeloid, Acute2
1CompletedTreatmentLeukemias11
1CompletedTreatmentLeukemias / Lymphoma NOS2
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes4
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood2
1CompletedTreatmentLymphoma NOS2
1CompletedTreatmentMyelogenous Leukemia, Acute3
1Not Yet RecruitingTreatmentAcute Lymphoid Leukemia (ALL) / Acute Myeloid Leukaemias (AML)1
1Not Yet RecruitingTreatmentDiffuse Large B Cell Lymphoma (DLBCL)1
1RecruitingTreatmentAML Arising After Exposure to Genotoxic Injury / AML Arising From Antecedent Hematologic Disorder (AHD) / AML Arising From Myelodysplastic Syndrome (MDS) / Newly Diagnosed Acute Myeloid Leukemia (AML) / Untreated AML1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / AML1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML)13
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia-2 / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Previously Treated Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome2
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Refractory Acute Myeloid Leukemia / Relapsed Acute Myeloid Leukemia1
1RecruitingTreatmentAcute Myeloid Leukemia, Relapsed, Adult1
1RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
1RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAdult Burkitt Lymphoma / Adult Diffuse Large B-Cell Lymphoma / CD20-Positive Neoplastic Cells Present / Indolent Adult Non-Hodgkin Lymphoma / Mantle Cell Lymphoma (MCL) / Recurrent B-Cell Non-Hodgkin Lymphoma / Refractory Mature B-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentContiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentHigh-risk Tumor / Lymphoma NOS / Neuroblastomas1
1RecruitingTreatmentLeukemia, Plasma Cell / Recurrent Plasma Cell Myeloma1
1RecruitingTreatmentLeukemias2
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentLymphoma, B-Cell1
1RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1RecruitingTreatmentMature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentDe Novo Myelodysplastic Syndrome / Mixed Phenotype Acute Leukemia (MPAL) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentMultiple Sclerosis (MS)1
1RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia1
1RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
1SuspendedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1SuspendedTreatmentPrimary Central Nervious System Lymphoma1
1TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Recurrent Pediatric ALL / Refractory Pediatric ALL / Relapsed Pediatric ALL1
1TerminatedTreatmentAcute Myelogenous Leukaemia (AML)1
1TerminatedTreatmentAllergy to Native e.Coli Asparaginase / Allergy to PEG e.Coli Asparaginase / Relapsed Acute Lymphoblastic Leukemia1
1TerminatedTreatmentLeukemia, Lymphoblastic, Acute, Philadelphia-Positive / Leukemia, Lymphocytic, Acute / Myelogenous Leukemia, Acute / Myelogenous Leukemia, Chronic, Aggressive Phase1
1TerminatedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Lymphoblastic, Acute, T Cell / Lymphoblastic Leukemia, Acute / Lymphoblastic Leukemia, Acute, Childhood1
1TerminatedTreatmentLeukemia, Myeloid, Acute1
1TerminatedTreatmentLeukemias1
1TerminatedTreatmentNeoplastic Meningitis1
1Unknown StatusTreatmentLeukemias1
1Unknown StatusTreatmentLeukemias / Lymphoma NOS1
1Unknown StatusTreatmentLymphoma NOS1
1WithdrawnTreatmentAML1
1WithdrawnTreatmentAcute Myeloid Leukaemias (AML)1
1WithdrawnTreatmentCNS 2a / CNS 2b / CNS 2c / CNS1 / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1WithdrawnTreatmentLeukemia, Erythroblastic, Acute / Leukemia, Megakaryoblastic, Acute / Leukemia, Monocytic, Acute / Leukemia, Myeloid, Acute / Leukemia, Myelomonocytic, Acute1
1WithdrawnTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
1WithdrawnTreatmentLymphoma NOS1
1, 2Active Not RecruitingTreatmentAcute Myeloblastic Leukemia1
1, 2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1, 2Active Not RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2Active Not RecruitingTreatmentLeukemia, Myeloid, Acute1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentLeukemias5
1, 2Active Not RecruitingTreatmentPreviously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML) / AML / Myelodysplastic Disorders1
1, 2CompletedTreatmentAML / MDS1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplastic Syndrome1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML)4
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Promyelocytic Leukemia (M3) / Recurrent Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentAcute Undifferentiated Leukemia (AUL) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / L1 Adult Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Adult Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Myelodysplastic Syndrome With Isolated Del(5q) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Relapsing Chronic Myelogenous Leukemia1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Thrombocytopenias1
1, 2CompletedTreatmentLeukemia, Myeloid, Acute1
1, 2CompletedTreatmentLeukemias6
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1, 2CompletedTreatmentLeukemias / Richter's Transformation1
1, 2CompletedTreatmentLymphoma NOS2
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMyelodysplastic Syndrome1
1, 2CompletedTreatmentMyelodysplastic Syndromes1
1, 2CompletedTreatmentMyeloid Leukemias1
1, 2CompletedTreatmentRecurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentRefractory Acute Leukemia / Relapsed Acute Leukemia1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2RecruitingTreatmentAML3
1, 2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Myeloid Leukaemias (AML) / De Novo Myelodysplastic Syndrome / Myeloproliferative Neoplasms1
1, 2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML)6
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myelodysplastic Syndrome1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1, 2RecruitingTreatmentAcute Myeloid Lukemia1
1, 2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma / Refractory T-Cell Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Plasmablastic Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Follicular Lymphoma / Stage III Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1, 2RecruitingTreatmentLeukaemia, Acute1
1, 2RecruitingTreatmentLeukemias3
1, 2RecruitingTreatmentPreviously Untreated Acute Myeloid Leukemia1
1, 2RecruitingTreatmentRelapsed/Refractory Acute Myeloid Leukemia (AML)1
1, 2TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myelodysplastic Syndromes1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Diffuse Large B-Cell Lymphoma (DLBCL) / Follicular Lymphoma Grade III (FL III°) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentAll / Burkitt's Lymphoma / CML / Leukaemia, Lymphoblastic1
1, 2TerminatedTreatmentAnaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma1
1, 2TerminatedTreatmentAstrocytomas / Glioblastoma Multiforme / Gliomas / Tumor, Brain1
1, 2TerminatedTreatmentChronic Myeloid Leukemia (CML)1
1, 2TerminatedTreatmentLeukemias1
1, 2TerminatedTreatmentMyelodysplastic Syndromes1
1, 2Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)1
1, 2Unknown StatusTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes (MDS)1
1, 2Unknown StatusTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Unknown StatusTreatmentLeukemias1
1, 2Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2WithdrawnTreatmentLeukemias1
1, 2WithdrawnTreatmentUntreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingPreventionAcute Myeloid Leukaemias (AML)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)2
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML)2
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (Megakaryoblastic) With t(1;22)(p13;q13); RBM15-MKL1 / Acute Myeloid Leukemia With a Variant RARA Translocation / Acute Myeloid Leukemia With Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 / Acute Myeloid Leukemia With t(6;9)(p23;q34); DEK-NUP214 / Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Acute Myeloid Leukemia With Variant MLL Translocations / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (Relapsed/Refractory)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Myelodysplasia-Related Changes / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myeloproliferative Neoplasm With 10% Blasts or Higher / Refractory Anemia With Excess Blasts / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Ph Positive Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentCentral Nervous System Lymphoma1
2Active Not RecruitingTreatmentChemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Lymphoma NOS / Neurotoxicity / Radiation Toxicity1
2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2Active Not RecruitingTreatmentDiffuse Large Cell Lymphoma / Lymphoma NOS1
2Active Not RecruitingTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentLeukaemia, Lymphoblastic / Lymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLeukemia, Myeloid, Acute1
2Active Not RecruitingTreatmentLeukemia-Lymphoma, Adult T-Cell1
2Active Not RecruitingTreatmentLeukemias4
2Active Not RecruitingTreatmentLymphoma NOS4
2Active Not RecruitingTreatmentLymphoma, B-Cell1
2Active Not RecruitingTreatmentLymphoma, Mantle-Cell / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2CompletedNot AvailableAcute Myelogenous Leukaemia (AML)1
2CompletedBasic ScienceAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Myeloproliferative/Myelodysplastic Neoplasm1
2CompletedDiagnosticAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
2CompletedDiagnosticLymphoma NOS1
2CompletedSupportive CareAnemias / Leukemias / Neutropenias / Thrombocytopenias1
2CompletedSupportive CareLymphoma NOS / Neutropenias1
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / AML / Leukemias1
2CompletedTreatmentAML / CML / Leukemias / MDS1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)4
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndromes1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)10
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Chronic Myeloid Leukemia (CML) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome3
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes (MDS)1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBurkitt's Lymphoma / Burkitt'S-like Lymphoma1
2CompletedTreatmentCarcinoma of the Prostate1
2CompletedTreatmentCentral Nervous System Metastases / Leptomeningeal Metastases / Recurrent Breast Cancer / Stage IV Breast Cancer / Tumors Metastatic to Brain1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentChronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia1
2CompletedTreatmentChronic Myeloproliferative Disorders1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Lymphoma NOS1
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
2CompletedTreatmentJuvenile Myelomonocytic Leukemia1
2CompletedTreatmentLeukaemia, Acute1
2CompletedTreatmentLeukaemia, Lymphoblastic / Lymphoma NOS1
2CompletedTreatmentLeukemia, Myelocytic, Acute2
2CompletedTreatmentLeukemia, Myeloid, Acute3
2CompletedTreatmentLeukemias37
2CompletedTreatmentLeukemias / Lymphoma NOS8
2CompletedTreatmentLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes3
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Neutropenias1
2CompletedTreatmentLeukemias / Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLupus Erythematosus, Systemic1
2CompletedTreatmentLymphoma NOS29
2CompletedTreatmentLymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentLymphoma, B Cell1
2CompletedTreatmentLymphoma, Mantle-Cell1
2CompletedTreatmentMultiple Sclerosis (MS) / Relapsing-Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentMyelodysplastic Syndromes / Myeloid Leukemias2
2CompletedTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentSarcomas1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Not Yet RecruitingTreatmentAML1
2Not Yet RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
2Not Yet RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission1
2Not Yet RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas1
2Not Yet RecruitingTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasms / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Not Yet RecruitingTreatmentDiffuse Large B Cell Lymphoma (DLBCL)1
2Not Yet RecruitingTreatmentMalignancies, Hematologic1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2Not Yet RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
2RecruitingBasic ScienceRecurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2RecruitingDiagnosticUntreated Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAML1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myelogenous Leukemia (CML) / Familial Hemophagocytic Lymphohistiocytosis (FLH) / Hemophagocytic Lymphohistiocytosis (HLH) / Myelodysplastic Syndrome / Non Hodgkins Lymphoma / Viral-associated Hemophagocytic Syndrome (VAHS) / X-linked Lymphoproliferative Disease (XLP)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemias1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML)12
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Acute Myeloid Leukemia With Multilineage Dysplasia / Sarcoma, Myeloid / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Therapy-Related Myelodysplastic Syndrome1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAutoimmune Diseases / Autoimmune Disorders1
2RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Hypodiploidy / Leukemia, Plasma Cell / Loss of Chromosome 17p / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T(14;16) / T(4;14) / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentB-cell Acute Lymphoblastic Leukemia1
2RecruitingTreatmentBurkitt's Lymphoma / CD20+ Lymphoblastic Lymphoma / Diffuse Large B-Cell Lymphoma (DLBCL) / Follicular Lymphoma, Grade III / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma1
2RecruitingTreatmentBurkitt's Lymphoma / Diffuse Large Cell Lymphoma / High Grade B-cell Lymphoma1
2RecruitingTreatmentDe Novo / Low-dose Corticosteroids Pretreatment / Secondary / Untreated Philadelphia Positive Acute Lymphoblastic Leukemia1
2RecruitingTreatmentDiffuse Large B Cell Lymphoma (DLBCL)1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2RecruitingTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-cell Lymphoma (DLBCL)1
2RecruitingTreatmentDiffuse Large Cell Lymphoma Relapsed/Refractory1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentGranulocytic Sarcoma / Recurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentHodgkins Disease (HD)1
2RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
2RecruitingTreatmentLarge B-cell Diffuse Lymphoma of Testis / Primary Testicular Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentLeptomeningeal Metastasis1
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemia, Lymphoblastic, Acute / Leukemias / Lymphoma, Lymphoblastic1
2RecruitingTreatmentLeukemias10
2RecruitingTreatmentLeukemias / Lymphoma NOS / Lymphoma, Lymphoblastic / Precursor-B Acute Lymphoblastic Leukemia1
2RecruitingTreatmentLymphoma NOS3
2RecruitingTreatmentLymphoma NOS / Lymphoma, Mantle-Cell1
2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2RecruitingTreatmentNewly Diagnosed AML With FLT3 Activating Mutations1
2RecruitingTreatmentPediatric Acute Myeloid Leukemia1
2RecruitingTreatmentPosttransplant Lymphoproliferative Disorder1
2RecruitingTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
2RecruitingTreatmentPrimary Disease1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentStage I Mantle Cell Lymphoma / Stage II Contiguous Mantle Cell Lymphoma / Stage II Non-Contiguous Mantle Cell Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Mantle Cell Lymphoma1
2RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2SuspendedTreatmentLymphoma NOS1
2TerminatedDiagnosticLymphoma NOS1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome / Sarcoma, Myeloid1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Lymphoid Leukemia (ALL) / Acute Myeloid Leukaemias (AML) / Mixed Lineage Acute Leukemia1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML)1
2TerminatedTreatmentAcute Myeloid Leukaemias (AML)3
2TerminatedTreatmentAcute Myeloid Leukaemias (AML) / High-risk Myelodysplastic Syndrome (MDS)1
2TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes1
2TerminatedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2TerminatedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
2TerminatedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / L3 Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma1
2TerminatedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive1
2TerminatedTreatmentBrain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Lymphoma NOS / Thrombocytopenias1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentLeukemia, Lymphoblastic, Acute / Leukemia, Myelogenous, Acute / Minimal Residual Disease1
2TerminatedTreatmentLeukemias3
2TerminatedTreatmentLeukemias / Lymphoma NOS1
2TerminatedTreatmentLymphoma NOS2
2TerminatedTreatmentLymphoma, B Cell / Neoplastic Meningitis1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentMyelodysplastic Syndromes, Myelogenous Leukemia, Acute1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentRelapsed Acute Myelogenous Leukemia1
2Unknown StatusSupportive CareChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Unknown StatusSupportive CareDrug/Agent Toxicity by Tissue/Organ / Leukemias / Myelodysplastic Syndromes / Neutropenias1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitts Leukemia/Lymphoma / Chronic Myelogenous Leukemia (CML) / Lymphoma, Lymphoblastic1
2Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)4
2Unknown StatusTreatmentAcute Myeloid Leukaemias (AML) / MDS1
2Unknown StatusTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2Unknown StatusTreatmentLeukemias6
2Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes1
2Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
2Unknown StatusTreatmentLymphoid Blastic Phase of Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia1
2Unknown StatusTreatmentLymphoma NOS7
2Unknown StatusTreatmentLymphoma NOS / Small Intestine Cancer1
2Unknown StatusTreatmentLymphoma, B-Cell1
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentNon Hodgkin Lymphoma (NHL)1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)3
2Unknown StatusTreatmentPrimary Non Hodgkin Lymphoma of the Central Nervous System1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias1
2WithdrawnTreatmentAcute Myelogenous Leukaemia (AML)1
2WithdrawnTreatmentAcute Myeloid Leukaemias (AML)1
2WithdrawnTreatmentAdult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS-Related1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentLymphoma NOS2
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2, 3CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentLeukemias / Lymphoma NOS / Myelodysplastic Syndromes1
2, 3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2, 3CompletedTreatmentLymphoma NOS1
2, 3Not Yet RecruitingTreatmentAdult Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-2 / Untreated Adult Acute Myeloid Leukemia1
2, 3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
2, 3RecruitingTreatmentLeukemias1
2, 3RecruitingTreatmentLymphoma, Lymphoblastic1
2, 3RecruitingTreatmentMature B-Cell Lymphoma1
2, 3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
2, 3Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
2, 3Unknown StatusTreatmentDe Novo Akute Myeloid Leukemia (AML) / Refractory Anemia With Excess of Blasts in Transformation / Secondary Acute Myeloid Leukemia (AML)1
2, 3Unknown StatusTreatmentLeukemias1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML)3
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentChildhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3Active Not RecruitingTreatmentChildhood Acute Promyelocytic Leukemia (M3) / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentHigh Risk Acute Myeloid Leukemia1
3Active Not RecruitingTreatmentLeukemia, Myeloid, Acute1
3Active Not RecruitingTreatmentLeukemias4
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentLymphoma NOS3
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
3CompletedSupportive CareCardiac Toxicity / Leukemias / Lymphoma NOS1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3CompletedTreatmentAcute Myelogenous Leukaemia (AML)2
3CompletedTreatmentAcute Myeloid Leukaemias (AML)3
3CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Erythroid Leukemia (M6) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
3CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
3CompletedTreatmentAdult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Promyelocytic Leukemia (M3) / Childhood Acute Promyelocytic Leukemia (M3) / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Lymphoma NOS / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChronic Myelogenous Leukemia (CML)1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemia, Promyelocytic, Acute1
3CompletedTreatmentLeukemias20
3CompletedTreatmentLeukemias / Lymphoma NOS4
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes4
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms3
3CompletedTreatmentLeukemias / Neutropenias1
3CompletedTreatmentLymphoma NOS6
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentMultiple Myeloma (MM)1
3Enrolling by InvitationTreatmentAcute Myeloid Leukemia, Adult1
3Not Yet RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3Not Yet RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
3Not Yet RecruitingTreatmentAcute Myeloid Leukemia, in Relapse1
3Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAML1
3RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Myeloid Leukaemias (AML)5
3RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Leukemias1
3RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
3RecruitingTreatmentAcute Myleoid Leukemia (AML)1
3RecruitingTreatmentAcute Promyelocytic Leukemia (APL)1
3RecruitingTreatmentAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Childhood Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3RecruitingTreatmentAdult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAdult B Lymphoblastic Lymphoma / Childhood B Acute Lymphoblastic Leukemia / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Lymphoblastic Lymphoma / Down Syndrome (DS) / Stage I B Lymphoblastic Lymphoma / Stage II B Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAdult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Bone Necrosis / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia2
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB-cell Non Hodgkin's Lymphoma / Mature B-cell Leukemia Burkitt-type1
3RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentChildhood Acute Myeloid Leukemia / Childhood Myelodysplastic Syndrome / Cytopenias / Down Syndrome (DS) / Myeloid Leukemia Associated With Down Syndrome / Myeloproliferative Neoplasms1
3RecruitingTreatmentLangerhans Cell Histiocytosis (LCH)1
3RecruitingTreatmentLeukaemia cutis / Sarcoma, Myeloid / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3RecruitingTreatmentLeukemia, Acute Myeloid (AML)1
3RecruitingTreatmentLeukemias1
3RecruitingTreatmentNeoplasms, Leukemia, Acute Myeloid Leukemia1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedPreventionAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentLymphoma NOS2
3TerminatedTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3Unknown StatusDiagnosticLeukemias / Myelodysplastic/Myeloproliferative Neoplasms1
3Unknown StatusTreatmentAcute Myelogenous Leukaemia (AML)1
3Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)3
3Unknown StatusTreatmentAcute Myeloid Leukaemias (AML) / Acute Nonlymphocytic Leukemia / Leukemias1
3Unknown StatusTreatmentDiffuse Large B-Cell Lymphoma (DLBCL) / IPI≥21
3Unknown StatusTreatmentLeukemias10
3Unknown StatusTreatmentLeukemias / Lymphoma NOS1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
3Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes2
3Unknown StatusTreatmentLeukemias / Neutropenias1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma NOS7
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMelanoma1
3Unknown StatusTreatmentSecondary Acute Myeloid Leukemia (Secondary AML, sAML)1
3WithdrawnTreatmentAcute Myeloid Leukaemias (AML)1
3WithdrawnTreatmentLeukemias2
4Active Not RecruitingPreventionAcute Myeloid Leukaemias (AML)1
4Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)5
4CompletedTreatmentAcute Myeloblastic Leukemia1
4CompletedTreatmentAcute Myeloblastic Leukemia / Myelodysplastic Syndrome1
4CompletedTreatmentAcute Myeloid Leukaemias (AML)1
4CompletedTreatmentAcute Promyelocytic Leukemia (APL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia4
4CompletedTreatmentBurkitt's Leukemia / Burkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentLymphoma, Lymphoblastic1
4Enrolling by InvitationTreatmentAcute Myeloid Leukaemias (AML)1
4Enrolling by InvitationTreatmentChildhood Acute Promyelocytic Leukemia1
4Not Yet RecruitingTreatmentLeukemias1
4RecruitingTreatmentAcute Lymphobkastic Leukemia1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)3
4RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Core-Binding Factor1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4Unknown StatusPreventionLeukemia, Promyelocytic, Acute1
4Unknown StatusTreatmentAcute Myeloid Leukaemias (AML) / AML1-ETO Fusion Protein Expression1
4Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL) / Non-Hodgkin's Lymphoma (NHL)1
4Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)2
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
Not AvailableActive Not RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Childhood Acute Myeloid Leukemia in Remission / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
Not AvailableActive Not RecruitingTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableActive Not RecruitingTreatmentChronic Myelomonocytic Leukemia-2 / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Untreated Adult Acute Myeloid Leukemia1
Not AvailableActive Not RecruitingTreatmentHodgkins Disease (HD) / Lymphoma NOS1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentLymphoma NOS1
Not AvailableCompletedTreatmentAML1
Not AvailableCompletedTreatmentAcute Myeloid Leukaemias (AML)1
Not AvailableCompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Refractory Anemia With Excess Blasts / Untreated Adult Acute Myeloid Leukemia1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Lymphoma NOS1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemias3
Not AvailableCompletedTreatmentLymphoma NOS1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentT-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableNo Longer AvailableNot AvailableLeukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis1
Not AvailableNot Yet RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Risk Stratification1
Not AvailableRecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / Mixed Phenotype Acute Leukemia (MPAL)1
Not AvailableRecruitingTreatmentAcute Myeloblastic Leukemia1
Not AvailableRecruitingTreatmentAcute Myeloid Leukaemias (AML)3
Not AvailableRecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myeloid Neoplasm1
Not AvailableRecruitingTreatmentLeukemias1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentMyelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
Not AvailableSuspendedTreatmentLeukemia, Myeloid, Acute1
Not AvailableTerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
Not AvailableTerminatedTreatmentCancers / Leukemias / Lymphoma NOS / Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentLeukemias / Lymphoma, Hodgkins / Myeloproliferative Disorders / Non Hodgkin Lymphoma (NHL)1
Not AvailableTerminatedTreatmentNeoplastic Meningitis1
Not AvailableTerminatedTreatmentSickle Cell Anemia / Sickle Cell-hemoglobin C Disease / Sickle Cell-β0-thalassemia1
Not AvailableUnknown StatusTreatmentLeukemias2
Not AvailableUnknown StatusTreatmentLymphoma NOS1
Not AvailableUnknown StatusTreatmentRetinoblastoma1
Not AvailableWithdrawnTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I AIDS-related Lymphoma / Stage II AIDS-related Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableWithdrawnTreatmentLymphoma NOS1
Pharmacoeconomics
Manufacturers
  • Pacira pharmaceuticals inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntrathecal; Intravenous; Subcutaneous100 mg/5mL
InjectionIntrathecal; Intravenous; Subcutaneous2 g/20mL
InjectionIntravenous; Subcutaneous20 mg/mL
Injection, solutionIntrathecal; Intravenous; Subcutaneous100 mg/mL
Injection, solutionIntrathecal; Intravenous; Subcutaneous20 mg/mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionIntravenous; Subcutaneous20 mg/mL
Powder, for solutionIntrathecal; Intravenous; Subcutaneous500 mg
LiquidIntravenous; Subcutaneous100 mg
SolutionIntrathecal; Intravenous; Subcutaneous100 mg
Powder, for solutionIntrathecal; Intravenous; Subcutaneous100 mg
Powder, for solutionIntrathecal; Intravenous; Subcutaneous1 g
Powder, for solutionIntrathecal; Intravenous; Subcutaneous2 g
SolutionIntrathecal; Intravenous; Subcutaneous20 mg
Injection, lipid complexIntrathecal50 mg/5mL
SuspensionIntrathecal10 mg
Injection, suspensionIntrathecal50 mg
Prices
Unit descriptionCostUnit
Depocyt 50 mg/5 ml vial588.0USD ml
Cytarabine 2 gm vial48.0USD vial
Cytarabine 1 gm vial24.0USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5455044 No1993-05-142013-05-14Us
US5723147 No1995-03-032015-03-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point186-188Hunter, J.H.; U S . Patent 3,116,282; December 31,1963; assigned to The Upjohn Company.
water solubilityFreely solubleNot Available
logP-2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility43.8 mg/mLALOGPS
logP-2.2ALOGPS
logP-2.8ChemAxon
logS-0.74ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)-0.55ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area128.61 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.54 m3·mol-1ChemAxon
Polarizability22.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9623
Blood Brain Barrier+0.9465
Caco-2 permeable-0.8887
P-glycoprotein substrateNon-substrate0.798
P-glycoprotein inhibitor INon-inhibitor0.9686
P-glycoprotein inhibitor IINon-inhibitor0.9532
Renal organic cation transporterNon-inhibitor0.9519
CYP450 2C9 substrateNon-substrate0.793
CYP450 2D6 substrateNon-substrate0.8613
CYP450 3A4 substrateNon-substrate0.6203
CYP450 1A2 substrateNon-inhibitor0.9543
CYP450 2C9 inhibitorNon-inhibitor0.9638
CYP450 2D6 inhibitorNon-inhibitor0.9497
CYP450 2C19 inhibitorNon-inhibitor0.9489
CYP450 3A4 inhibitorNon-inhibitor0.9609
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.981
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9158
BiodegradationNot ready biodegradable0.7807
Rat acute toxicity1.7184 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.983
hERG inhibition (predictor II)Non-inhibitor0.911
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-0006-0190000000-eff861edb69ddab2c195View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-0a4i-0900000000-4b5b14f0a5467db173b6View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-0a4i-3900000000-d85ae6c771dd9206c4c2View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-06sl-9600000000-b154ca170372bcbf8a4aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ , negativesplash10-00lu-9200000000-840df44a2d1149f4a7f7View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyrimidine nucleosides. These are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety.
KingdomOrganic compounds
Super ClassNucleosides, nucleotides, and analogues
ClassPyrimidine nucleosides
Sub ClassNot Available
Direct ParentPyrimidine nucleosides
Alternative Parents
Substituents
  • Pyrimidine nucleoside
  • Glycosyl compound
  • N-glycosyl compound
  • Pentose monosaccharide
  • Aminopyrimidine
  • Pyrimidone
  • Hydropyrimidine
  • Monosaccharide
  • Pyrimidine
  • Imidolactam
  • Tetrahydrofuran
  • Heteroaromatic compound
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Organic nitrogen compound
  • Primary alcohol
  • Organic oxide
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Organopnictogen compound
  • Organic oxygen compound
  • Primary amine
  • Hydrocarbon derivative
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Prakasha Gowda AS, Polizzi JM, Eckert KA, Spratt TE: Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1. Biochemistry. 2010 Jun 15;49(23):4833-40. doi: 10.1021/bi100200c. [PubMed:20459144 ]
  2. Foti M, Omichinski JG, Stahl S, Maloney D, West J, Schweitzer BI: Effects of nucleoside analog incorporation on DNA binding to the DNA binding domain of the GATA-1 erythroid transcription factor. FEBS Lett. 1999 Feb 5;444(1):47-53. [PubMed:10037146 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Microtubule binding
Specific Function:
Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA po...
Gene Name:
POLB
Uniprot ID:
P06746
Molecular Weight:
38177.34 Da
References
  1. Angeli JP, Ribeiro LR, Bellini MF, Mantovanil: Anti-clastogenic effect of beta-glucan extracted from barley towards chemically induced DNA damage in rodent cells. Hum Exp Toxicol. 2006 Jun;25(6):319-24. [PubMed:16866189 ]
  2. Miura S, Izuta S: DNA polymerases as targets of anticancer nucleosides. Curr Drug Targets. 2004 Feb;5(2):191-5. [PubMed:15011952 ]
  3. Krynetskaia NF, Phadke MS, Jadhav SH, Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. doi: 10.1158/1535-7163.MCT-08-0695. [PubMed:19372559 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
This enzyme scavenges exogenous and endogenous cytidine and 2'-deoxycytidine for UMP synthesis.
Gene Name:
CDA
Uniprot ID:
P32320
Molecular Weight:
16184.545 Da
References
  1. Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, Komada Y: Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep. 2004 Nov;12(5):1115-20. [PubMed:15492802 ]
  2. Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. [PubMed:19842938 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
Gene Name:
DCK
Uniprot ID:
P27707
Molecular Weight:
30518.315 Da
References
  1. Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, Komada Y: Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep. 2004 Nov;12(5):1115-20. [PubMed:15492802 ]
  2. Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. [PubMed:19842938 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nucleotide binding
Specific Function:
Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
Gene Name:
NT5E
Uniprot ID:
P21589
Molecular Weight:
63367.255 Da
References
  1. Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. [PubMed:19842938 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Zinc ion binding
Specific Function:
Supplies the nucleotide substrate for thymidylate synthetase.
Gene Name:
DCTD
Uniprot ID:
P32321
Molecular Weight:
20015.805 Da
References
  1. Lamba JK: Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. doi: 10.2217/pgs.09.118. [PubMed:19842938 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Chen R, Nelson JA: Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol. 2000 Jul 15;60(2):215-9. [PubMed:10825466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Chen R, Nelson JA: Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol. 2000 Jul 15;60(2):215-9. [PubMed:10825466 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nucleoside transmembrane transporter activity
Specific Function:
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR) and is sodium-independent. It has a higher affinity for adenosine. Inhibited by dipyridamole and dilazep (anticancer chemotherapeutics drugs).
Gene Name:
SLC29A1
Uniprot ID:
Q99808
Molecular Weight:
50218.805 Da
References
  1. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010 May;223(2):384-8. doi: 10.1002/jcp.22045. [PubMed:20082300 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23